Concert Pharmaceuticals Announces Upcoming Poster Presentation at North American Cystic Fibrosis Conference
September 21 2016 - 4:01PM
Business Wire
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced
that the Company will present a poster at the 30th Annual North
American Cystic Fibrosis Conference being held October 27-29, 2016,
in Orlando, Florida. Data describing the relative bioavailability
of CTP-656 under fasted and fed conditions along with results from
the Phase 1 multiple ascending dose study will be presented.
Details on the upcoming poster presentation follow below.
- Abstract Title: CTP-656 Multiple Dose
Pharmacokinetic Profile Continues to Support a Once-Daily
Potentiator for Cystic Fibrosis Patients with Gating Mutations
- Poster Session I: Thursday, October 27,
11:15 a.m.-1:45 p.m.
- Poster Number: 224
About CTP-656 and Cystic Fibrosis
CTP-656 is a novel CFTR potentiator that may offer next
generation, once-daily dosing and was developed by Concert’s
application of its novel deuterium chemistry to modify ivacaftor.
Concert is initially developing CTP-656 as a potential monotherapy
treatment for cystic fibrosis due to gating mutations of the gene
that encodes for cystic fibrosis transmembrane conductance
regulator (CFTR), a protein, which regulates components of sweat,
mucus clearance and digestion. Cystic fibrosis is a
life-threatening, hereditary genetic disease that has systemic
effects and can cause significantly reduced lung and digestive
system function. According to the Cystic Fibrosis Foundation, an
estimated 70,000 people worldwide have cystic fibrosis.
About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical
company focused on applying its DCE Platform® (deuterated chemical
entity platform) to create novel medicines designed to address
unmet patient needs. The Company’s approach starts with approved
drugs in which deuterium substitution has the potential to enhance
clinical safety, tolerability or efficacy. Concert has a broad
pipeline of innovative medicines targeting pulmonary diseases,
including cystic fibrosis, central nervous systems (CNS) disorders,
as well as autoimmune and inflammatory diseases. For more
information please visit www.concertpharma.com.
Concert Pharmaceuticals Inc., the CoNCERT
Pharmaceuticals Inc. logo and DCE Platform are registered
trademarks of Concert Pharmaceuticals, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160921006475/en/
Concert Pharmaceuticals, Inc.Justine E. Koenigsberg,
781-674-5284ir@concertpharma.com
Concert Pharmaceuticals (NASDAQ:CNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Concert Pharmaceuticals (NASDAQ:CNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024